Zika Virus Antibody, IgM

Laboratory assay overview

This test is intended for the presumptive qualitative detection of Zika virus IgM antibodies in serum from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and epidemiological criteria for Zika virus testing. Zika viruses are primarily transmitted by Aedes aegypti and Aedes albopictus mosquitos [1]. Most individuals with a Zika virus infection are asymptomatic. Individuals with symptomatic infections may experience fever, rash, and muscle/joint pain [2]. Per the 2019 CDC guidelines, a nucleic acid amplification test (NAAT) and an IgM antibody test should be performed on maternal serum and a NAAT on maternal urine for pregnant women who live in or have traveled (during the pregnancy) to geographic areas at risk for Zika and who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection. For current testing guidelines, see Testing Guidance | Zika Virus | CDC. Zika infection shares clinical and epidemiological features with other arbovirus infections such as Dengue and Chikungunya. For CDC guidelines on testing concurrently for Zika and Dengue, see Testing Guidance | Dengue | CDC. Serologic results may be difficult to interpret due to cross-reactivity between Zika IgM and Dengue IgM antibodies. If Zika virus NAAT results are negative, a presumptive positive Zika IgM result requires additional confirmatory testing. Zika IgM antibodies can persist for months or years following infection. Therefore, the presence of Zika IgM antibodies may not indicate a recent infection. 1. Subcommittee on Laboratory Practices, ASM, and Public Relations Committee, Pan American Society for Clinical Virology (PASCV). Zika virus: An Update on the Disease and Guidance for Laboratory Testing. September 2022. Accessed May 9, 2023. Zika Virus: An Update on the Disease and Guidance for Laboratory Testing | ASM.org. 2. Sharp TM, et al. MMWR Recomm Rep. 2019 Jun 14;68(1):1-10.

Laboratory assay overview

Presumptive qualitative detection of Zika virus IgM antibodies in human sera collected from individuals meeting CDC Zika virus clinical criteria (eg, a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (eg, history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated).

Laboratory assay overview

This panel is intended for the qualitative detection of Zika virus in serum and urine and the presumptive qualitative detection of Zika virus IgM antibodies in serum from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and epidemiological criteria for Zika virus testing. Zika viruses are primarily transmitted by Aedes aegypti and Aedes albopictus mosquitos [1]. Most individuals with Zika infections are asymptomatic. Individuals with symptomatic infections may experience fever, rash, and muscle/joint pain [2]. Per the 2019 CDC guidelines, a nucleic acid amplification test (NAAT) and an IgM antibody test should be performed on maternal serum and a NAAT on maternal urine for pregnant women who live in or have traveled (during the pregnancy) to geographic areas at risk for Zika and who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection. For current testing guidelines, see https://www.cdc.gov/zika/hc-providers/testing-guidance.html Zika infection shares clinical and epidemiological features with other arbovirus infections such as Dengue and Chikungunya. For CDC guidelines on testing concurrently for Zika and Dengue, see https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html. Serologic results may be difficult to interpret due to cross-reactivity between Zika IgM and Dengue IgM antibodies. If Zika virus NAAT results are negative, a presumptive positive Zika IgM result requires additional confirmatory testing. Zika IgM antibodies can persist for months or years following infection. Therefore, the presence of Zika IgM antibodies may not indicate a recent infection. 1. Subcommittee on Laboratory Practices, ASM, and Public Relations Committee, Pan American Society for Clinical Virology (PASCV). Zika Virus: An Update on the Disease and Guidance for Laboratory Testing. September 2022. Accessed May 9, 2023. https://asm.org/Guideline/Zika-virus-An-update-on-the-disease-and-guidance-f. 2. Sharp TM, et al. MMWR Recomm Rep. 2019 Jun 14;68(1):1-10.